瑞丹韦单抗INN:Regdanvimab),以商品名Regkirona出售,是一种用于治疗COVID-19的人单克隆抗体[4]该抗体针对SARS-CoV-2刺突蛋白。它是由赛特瑞恩(Celltrion)开发的。[6][7]该药物通过静脉输注(滴注)给药。[4][8]

瑞丹韦单抗
单克隆抗体
种类完整抗体
目標SARS-CoV-2刺突蛋白
臨床資料
商品名英语Drug nomenclatureRegkirona
其他名稱瑞达韦单抗、瑞丹维单抗、CT-P59
核准狀況
懷孕分級
给药途径静脉注射
ATC碼
法律規範狀態
法律規範
识别信息
CAS号2444308-95-4
DrugBank
UNII
KEGG

最常见的副作用包括输液相关反应,包括过敏反应过敏性休克[4]

瑞丹韦单抗于2021年11月在欧盟获批用于医疗用途。[4][5]

参考资料

编辑
  1. ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 12 May 2022 [13 May 2022]. (原始内容存档于3 April 2022). 
  2. ^ AusPAR: Regdanvimab. Therapeutic Goods Administration (TGA). 7 December 2021 [4 January 2022]. (原始内容存档于5 January 2022). 
  3. ^ TGA Provisional Approval of Celltrion Healthcare Australia Pty Ltd COVID-19 treatment, regdanvimab (Regkirona). Therapeutic Goods Administration (TGA) (新闻稿). 6 December 2021 [4 January 2022]. (原始内容存档于5 January 2022). 
  4. ^ 4.0 4.1 4.2 4.3 4.4 Regkirona EPAR. European Medicines Agency. 10 November 2021 [12 November 2021]. (原始内容存档于12 November 2021).  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ 5.0 5.1 Regkirona. Union Register of medicinal products. 12 November 2021 [24 April 2022]. (原始内容存档于24 April 2022). 
  6. ^ Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform (新闻稿). Celltrion. 11 February 2021 [4 March 2021]. (原始内容存档于19 October 2021) –通过Business Wire. 
  7. ^ Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59 (新闻稿). Celltrion. 13 January 2021 [4 March 2021]. (原始内容存档于19 October 2021) –通过Business Wire. 
  8. ^ EMA issues advice on use of regdanvimab for treating COVID-19. European Medicines Agency. 26 March 2021 [15 October 2021]. (原始内容存档于15 November 2021). 

延伸阅读

编辑

外部链接

编辑
  • Regdanvimab. Drug Information Portal. U.S. National Library of Medicine. [2023-12-19]. (原始内容存档于2022-11-27).